We at Blood Centers of America are ardent believers in the future of decentralized manufacturing of cell therapies in highly-controlled, closed, automated systems such as those blood centers have been using for years to process blood and blood components supplies to hospitals every day. Indeed, late last year we made a submission to the FDA outlining our position that the national footprint of blood centers local to the entire US healthcare system was perfectly and best positioned to provide the kind of footprint needed in a future in which decentralized manufacturing of cell-based therapies was possible and permitted. Even though we don’t believe that “decentralized” should be confused with “point-of-care”, here’s a great article discussing some key aspects around this trend:
.
